Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma
出版年份 2009 全文链接
标题
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 9, Issue 6, Pages 795-805
出版商
Informa UK Limited
发表日期
2009-06-05
DOI
10.1586/era.09.29
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
- (2008) David Chu et al. ACTA ONCOLOGICA
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
- (2008) M. L. Telli et al. ANNALS OF ONCOLOGY
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
- (2008) M. E. Lacouture et al. ANNALS OF ONCOLOGY
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
- (2008) C Le Tourneau et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma
- (2008) Brian I. Rini et al. CANCER
- Heart failure associated with sunitinib malate
- (2008) Aarif Y. Khakoo et al. CANCER
- Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
- (2008) Mathis Grossmann et al. CLINICAL ENDOCRINOLOGY
- Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma
- (2008) Thomas W. Flaig et al. INVESTIGATIONAL NEW DRUGS
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib
- (2008) Natascha A.J.B. Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
- (2008) Toni K. Choueiri et al. JOURNAL OF UROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
- Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
- (2008) M. E. Lacouture et al. ONCOLOGIST
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
- (2008) T. E. Hutson et al. ONCOLOGIST
- Posterior reversible encephalopathy syndrome during sunitinib therapy
- (2008) R. Cumurciuc et al. REVUE NEUROLOGIQUE
- Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
- (2008) S. E. Rosenbaum et al. SUPPORTIVE CARE IN CANCER
- The changing face of renal cell carcinoma pathology
- (2008) Hakan Aydin et al. Current Oncology Reports
- Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
- (2007) I. Tamaskar et al. ANNALS OF ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started